Diagnosis of arrhythmogenic right ventricular cardiomyopathy
Matthew N. Peters, MD, Morgan J. Katz, MD, and Mohi E. Alkadri, MD Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an infrequently diagnosed condition with a high incidence of sudden cardiac death. While the only option for cure is orthotopic cardiac transplantation, the use of an implantable cardiac defibrillator can be life saving. Accordingly, the prompt recognition of ARVC is crucial. Fortunately, a definitive diagnosis of ARVC can often be made by a combination of the clinical history and electrocardiogram alone, as illustrated by the present case. In our patient, who presented with multiple syncopal episodes and in whom ventricular tachycardia was observed shortly after her admission to the emergency department, a lengthy and expensive workup was initiated, which ultimately may have delayed implantation of an implantable cardiac defibrillator. Clinicians should be made aware of the clinical guidelines for dealing with this potentially dangerous condition so that appropriate therapy can be promptly initiated.
W e report the case of a woman who presented to our emergency department with multiple syncopal episodes. She was subsequently found to have arrhythmogenic right ventricular cardiomyopathy (ARVC), an infrequently diagnosed condition with a high incidence of sudden cardiac death (SCD). Our case highlights how ARVC can be rapidly diagnosed with a combination of clinical history and an electrocardiogram (ECG), avoiding a lengthy and expensive diagnostic workup.
CASE REPORT
A 62-year-old woman with no prior cardiac history presented with a several-week history of recurrent palpitations and near syncope. She reported taking no medications and denied any relevant cardiac family history. Two weeks prior to her current visit, she had been seen for similar complaints and had an extensive diagnostic workup that included blood chemistry testing, ECG, exercise stress echocardiography, and a computed tomography scan on a pulmonary embolism protocol. Despite a completely negative diagnostic workup, the patient's symptoms continued to increase in frequency and duration.
Upon presentation to the emergency department, the patient was found to have multiple episodes of a wide-complex tachycardia at a rate of 150 beats per minute, which was noted on telemetry. Baseline ECG revealed a right bundle branch block, inverted T waves in the anterior precordial leads, and epsilon waves (low amplitude signals between the end of the QRS complexes and the onset of the T waves; see arrows) ( Figure 1) . Subsequent ECGs documented a monomorphic wide QRS complex tachycardia suggestive of ventricular tachycardia (VT) with left bundle branch morphology and superior axis (Figure 2 ). Given the combination of the patient's clinical presentation and ECG fi ndings, ARVC was suspected. Subsequent cardiac magnetic resonance imaging revealed areas of right ventricular free wall microaneurysms and wall motion abnormalities with corresponding late gadolinium enhancement, also suggestive of ARVC.
Th e following day, the patient was brought to the electrophysiology lab, where VT was easily inducible. Following endocardial mapping of the arrhythmia, radiofrequency ablation was applied to 13 sites near the right ventricular apex, and VT was no longer inducible at the end of the procedure. Over the next 48 hours, the patient remained asymptomatic, and no further episodes of VT were seen on the monitor. Th e patient was sent home but returned to the hospital less than 1 week later complaining of multiple episodes of near syncope and was found to have recurrent VT. Th e following day the patient was taken to the electrophysiology lab for implantable cardiac defi brillator (ICD) placement. Six months later, the patient has experienced no recurrence of syncope or presyncopal episodes.
DISCUSSION
ARVC was fi rst described in 1977, and the clinical manifestations include recurrent ventricular arrhythmias, right ventricular failure, and SCD (1) . Th e prevalence of ARVC is estimated to be between 1 in 2000 and 1 in 5000, and it can be inherited in both autosomal dominant and autosomal recessive patterns (2, 3) . ARVC is three times more common in women, and the average age of onset of clinical symptoms is 29 (3). While ARVC accounts for up to 11% of all cases of SCD in Italy (22% of SCD in athletes), it is rarely diagnosed in the United States, possibly due to underdiagnosis (2) . SCD is the third most common presenting symptom (behind syncope and palpitations) and is the initial symptom in 23% of cases (4) . Consequently, an increased awareness and prompt recognition of ARVC has considerable life-saving potential.
In 2010, Marcus et al published a proposed modifi cation of the task force criteria for the diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia (revising previously established 1994 criteria) (5). In the 2010 modifi cation, there are six major categories, divided into major and minor criteria (Table) (5) . Based on these criteria, the diagnosis can be stratifi ed as defi nitive with fulfi llment of as few as two major or one major and two minor criteria (5) . Utilizing these criteria, it may be possible to avoid further diagnostic studies that can be both invasive and expensive. For example, right ventricular biopsy has traditionally been used as a confi rmatory test in ARVC. However, due to the patchy distribution of the fi brosis and the fact that intramyocardial fat often occurs in anterolateral and apical regions of the heart in normal individuals, there is a fairly high incidence of both false-positives and false-negatives (6) . Similarly, while cardiac magnetic resonance allows for the identifi cation of global and regional ventricular dilation, the presence of intramyocardial fat, focal wall thinning, and the occurrence of late gadolinium enhancement, it has the disadvantage of a high false-positive rate and considerable interobserver variability (7). In contrast, echocardiography, which is considerably cheaper, has been shown to have a diagnostic specifi city as high as 95% (8) . Th us, we propose that cardiac magnetic resonance may be more useful when the clinical suspicion is high but when neither the ECG nor echocardiographic fi ndings are defi nitive, as might occur early in the disease process or with family members of aff ected patients.
Treatment of ARVC has remained disappointing, as the only curative option is orthotopic cardiac transplantation, which is considered only in individuals with progressive heart failure or intractable ventricular arrhythmia. Radiofrequency ablation has proven largely palliative in that it may eradicate some arrhythmogenic foci but the patchy and progressive nature of the disease almost invariably causes new foci to emerge (9) . Accordingly, radiofrequency ablation is currently reserved for patients who experience frequent ventricular arrhythmias (and ICD shocks) despite optimal therapy with both ICDs and antiarrhythmic medication (10) . It should be noted, however, that the role of radiofrequency ablation may continue to increase in the future, as mapping techniques continue to evolve.
Currently, the 2006 guidelines from the American College of Cardiology, American Heart Association, and European Society of Cardiology recommend ICD implantation for secondary prevention in all patients with prior sustained VT or ventricular fi brillation and for primary prevention in a selected high-risk group of patients (11) . Th is high-risk group includes patients with extensive disease, those with a family history of SCD, and young patients, as evidenced by a decrease in the odds ratio (0.77) for SCD for every 5 years of age (4, 11) . Following ICD implantation, adjunctive therapy with antiarrhythmic drugs, especially sotalol and amiodarone, is often employed to prevent subsequent ICD shocks (11) .
While ICDs are currently the first-line treatment option for ARVC, several issues can render ICDs both less eff ective and potentially riskier than in individuals with other types of heart disease. Th e 2006 guidelines note that fibrofatty changes in the right ventricle of ARVC patients may interfere with adequate lead positioning and arrhythmia sensing (11) . Additionally, patients with ARVC often have thin right ventricular walls that can predispose them to perforation, a risk that becomes even greater when considering that multiple ICD lead replacements may be necessary, given the relatively young age of onset typical of ARVC (11) .
Attention should also be focused on identifi cation of ARVC in associated family members. Twelve types of ARVC have been identifi ed and mapped to mutations in diff erent chromosomes, leading to defective cell adhesion and myocardial sarcoplasmic reticulum calcium release (12) . All 12 types of ARVC can be inherited in an autosomal dominant fashion. Consequently, ARVC has proved to be familial in 30% of cases (13) . Accordingly, it is currently recommended that family members of ARVC patients abstain from high-intensity activity until adequate genetic screening can be carried out. 
